A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ONCE-WEEKLY CT-388 ADMINISTERED SUBCUTANEOUSLY FOR 48 WEEKS TO PARTICIPANTS WHO ARE OVERWEIGHT OR OBESE WITH TYPE 2 DIABETES MELLITUS
- Registry ID
- CT-388-104 (XC45544)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2025-07-16
- Last update
- 2025-06-20
Conditions
- OVERWEIGHT/OBESITY
- TYPE 2 DIABETES
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE II, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, 42-WEEK DOSE-FINDING TRIAL FOR BI 3034701 ADMINISTERED SUBCUTANEOUSLY COMPARED TO PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT
- A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF ELECOGLIPRON IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS (EMBOLD)
- A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-3)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
View on source registry